Bank Of Montreal Immuno Gen, Inc. Transaction History

Bank Of Montreal

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$12.46 - $29.95 $42,949 - $103,237	-3,447 Reduced 2.79%	120,073 $3.56 Million
Q3 2023 Nov 01, 2023	SELL	$14.09 - $19.87 $2.79 Million - $3.94 Million	-198,175 Reduced 61.6%	123,520 $1.96 Million
Q2 2023 Aug 02, 2023	BUY	$3.75 - $20.05 $861,847 - $4.61 Million	229,826 Added 250.17%	321,695 $6.07 Million
Q1 2023 Jun 13, 2024	BUY	$3.67 - $4.92 $473,169 - $634,330	128,929 New	128,929 $495,000
Q4 2022 Feb 01, 2023	BUY	$4.55 - $6.31 $346,300 - $480,254	76,110 Added 482.96%	91,869 $455,000
Q3 2022 Nov 10, 2022	BUY	$4.48 - $6.47 $21,365 - $30,855	4,769 Added 43.39%	15,759 $82,000
Q2 2022 Aug 11, 2022	BUY	$3.15 - $5.76 $34,618 - $63,302	10,990 New	10,990 $47,000
Q1 2022 May 12, 2022	SELL	$4.26 - $7.48 $2.78 Million - $4.88 Million	-652,756 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$4.75 - $7.5 $3.1 Million - $4.9 Million	652,756 New	652,756 $4.88 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.